https://www.selleckchem.com/pr....oducts/Hesperadin.ht
Aim Immune checkpoint inhibitors (ICIs) have dramatically changed the treatment paradigm in patients with non-small-cell lung cancer (NSCLC). However, progression patterns with immunotherapy are currently unclear and therapeutic options beyond resistance remain challenging. Methods We reviewed advanced NSCLC patients between January 2016 and December 2019 who were treated with anti-PD-1/PD-L1 inhibitors in our center and identified those who developed disease progression. Later-line treatment strategies were collected and objective r
Мне нравится
Комментарий
Перепост
Victoria Wilburn
Удалить комментарий
Вы уверены, что хотите удалить этот комментарий?
Victoria Wilburn
Удалить комментарий
Вы уверены, что хотите удалить этот комментарий?